Abeona Therapeutics (ABEO) Stock Price, Quote & News

Company Profile

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 813 4701

Website: www.abeonatherapeutics.com

Address:

6555 Carnegie Avenue, 4th Floor, Cleveland, United States

tmoney4572 May. 9 at 11:03 PM

$ABEO

0 · Reply

alexpitti May. 8 at 8:04 PM

$ABEO no offense but we all been making predictions for 2 months. I'm done. Have A good mothers day and come back Wednesday 😂

1 · Reply

Po556677 May. 8 at 7:32 PM

$ABEO Any predictions for next week?I feel good earnings are before the bell for.... what its worth

2 · Reply

alexpitti May. 8 at 4:18 PM

no one should care about the day to day movements at this point. we will find out on wednesday anyway. $ABEO

0 · Reply

savvy_1 May. 8 at 4:10 PM

$ABEO Short pattern set up on the intraday under $5.87 and on the daily chart under $5.60. I'm not short but long. Just pointing it out as something to watch. I have a long position and a position I trade. Staying above $5.78 is important technically.

0 · Reply

GeniusLoci May. 8 at 4:04 PM

$ABEO Although nothing in common with URGN, ABEO also received a permanent J-code on January 1, which should provide a significant synergistic effect on sales

0 · Reply

Abelixe May. 8 at 2:41 PM

$ABEO

0 · Reply

creditgoo May. 7 at 4:48 PM

$ABEO lol

1 · Reply

tmoney4572 May. 7 at 4:20 PM

$ABEO RSI too hot. Gotta let that baby cool. See you at 5.50. Then we sprint toward earnings

1 · Reply

kikitan May. 7 at 4:08 PM

$ABEO waiting patiently for a big dip to buy more!

2 · Reply

Abeona Therapeutics® Announces Date of First Quarter Financial Results

May 1, 2026, 8:30 AM EDT - 9 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 7, 2026, 8:30 AM EDT - 4 weeks ago

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Apr 2, 2026, 8:30 AM EDT - 5 weeks ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

2026-03-17T21:40:20.000Z - 7 weeks ago

Abeona Therapeutics price target lowered to $20 from $27.50 at Alliance Global

Mar 17, 2026, 8:30 AM EDT - 7 weeks ago

Abeona Therapeutics Earnings Call Transcript: Q4 2025

2026-03-17T12:05:19.000Z - 7 weeks ago

Options Volatility and Implied Earnings Moves Today, March 17, 2026

ASO DOCU HITI HUYA LULU QFIN TME

2026-03-17T11:35:14.000Z - 7 weeks ago

Abeona Therapeutics reports 2025 EPS $1.01 vs. ($1.55) last year

Mar 17, 2026, 7:30 AM EDT - 7 weeks ago

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Abeona Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:41:57.000Z - 2 months ago

Abeona Therapeutics provides business update on momentum in Zevaskyn launch

Mar 9, 2026, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Mar 3, 2026, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

2025-12-31T12:35:26.000Z - 4 months ago

Abeona Therapeutics announces employee inducement grants

2025-12-15T12:36:04.000Z - 5 months ago

Abeona Therapeutics appoints Mohamad Tabrizi as CBO

Dec 15, 2025, 7:30 AM EST - 5 months ago

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

2025-12-11T12:35:25.000Z - 5 months ago

Abeona Therapeutics announces new treatment center for Zevaskyn in Texas

Dec 11, 2025, 7:30 AM EST - 5 months ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

2025-12-08T12:35:33.000Z - 5 months ago

Abeona Therapeutics announces first patient treatment with ZEVASKYN

Dec 8, 2025, 7:30 AM EST - 5 months ago

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

2025-12-01T12:35:41.000Z - 5 months ago

Abeona Therapeutics reports employee inducement grants

Nov 13, 2025, 1:20 PM EST - 6 months ago

Abeona Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-12T19:20:27.000Z - 6 months ago

Abeona Therapeutics price target lowered to $19 from $20 at Stifel

Nov 12, 2025, 8:30 AM EST - 6 months ago

Abeona Therapeutics Earnings Call Transcript: Q3 2025

2025-11-12T12:36:04.000Z - 6 months ago

Abeona Therapeutics reports Q3 EPS (10c), consensus (34c)

2025-11-12T12:35:51.000Z - 6 months ago

Abeona Therapeutics sees cash runway for over two years

Nov 12, 2025, 7:30 AM EST - 6 months ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 6 months ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

2025-11-03T12:35:07.000Z - 6 months ago

Abeona Therapeutics announces employee inducement grants

2025-10-30T14:50:28.000Z - 6 months ago

Abeona Therapeutics announces permanent J-Code for ZEVASKYN

Oct 30, 2025, 10:45 AM EDT - 6 months ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

2025-10-20T12:47:35.000Z - 7 months ago

Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development

Oct 20, 2025, 8:30 AM EDT - 7 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

2025-10-13T11:35:17.000Z - 7 months ago

Abeona Therapeutics announces ABO-503 gene therapy for XLRS selected by FDA

Oct 13, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

2025-10-08T11:36:41.000Z - 7 months ago

Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN

Oct 8, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Sep 9, 2025, 2:00 PM EDT - 8 months ago

Abeona Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 10:20 AM EDT - 8 months ago

Abeona Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics Earnings Call Transcript: Q2 2025

Jul 29, 2025, 10:00 AM EDT - 10 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 15, 2025, 7:30 AM EDT - 10 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 14, 2025, 7:00 AM EDT - 10 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Jul 2, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 1, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jun 30, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 24, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 4, 2025, 11:40 AM EDT - 1 year ago

Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 8:46 AM EDT - 1 year ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q1 2025

May 14, 2025, 8:07 AM EDT - 1 year ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Apr 29, 2025, 6:06 AM EDT - 1 year ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 1 year ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q4 2024

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Abeona Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

Abeona Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Sep 19, 2024, 9:45 AM EDT - 1 year ago

Abeona Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 1:30 PM EDT - 1 year ago

Abeona Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 11, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 9, 2024, 9:45 AM EDT - 1 year ago

Abeona Therapeutics Transcript: Stifel Virtual Cell Therapy Forum

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 8:30 AM EDT - 2 years ago

Abeona Therapeutics Earnings Call Transcript: Q1 2024

May 15, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

May 3, 2024, 7:30 AM EDT - 2 years ago

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

tmoney4572 May. 9 at 11:03 PM

$ABEO

0 · Reply

alexpitti May. 8 at 8:04 PM

$ABEO no offense but we all been making predictions for 2 months. I'm done. Have A good mothers day and come back Wednesday 😂

1 · Reply

Po556677 May. 8 at 7:32 PM

$ABEO Any predictions for next week?I feel good earnings are before the bell for.... what its worth

2 · Reply

alexpitti May. 8 at 4:18 PM

no one should care about the day to day movements at this point. we will find out on wednesday anyway. $ABEO

0 · Reply

savvy_1 May. 8 at 4:10 PM

0 · Reply

GeniusLoci May. 8 at 4:04 PM

$ABEO Although nothing in common with URGN, ABEO also received a permanent J-code on January 1, which should provide a significant synergistic effect on sales

0 · Reply

Abelixe May. 8 at 2:41 PM

$ABEO

0 · Reply

creditgoo May. 7 at 4:48 PM

$ABEO lol

1 · Reply

tmoney4572 May. 7 at 4:20 PM

$ABEO RSI too hot. Gotta let that baby cool. See you at 5.50. Then we sprint toward earnings

1 · Reply

kikitan May. 7 at 4:08 PM

$ABEO waiting patiently for a big dip to buy more!

2 · Reply

FitzCatalyst May. 7 at 3:36 PM

$ABEO sector dump

2 · Reply

Cautiousamphybian May. 7 at 1:11 PM

$ABEO When do people think we'll start to see a heavy volume of the 7.6m outstanding warrants at $4.75 being exercised? Does anyone think it's already started or will holders wait until after Q1 earnings looking to exercise into any high volume spikes in share price?

2 · Reply

Pharma3000 May. 7 at 7:15 AM

$ABEO 6.80$ would be nice before the Q1 call

1 · Reply

GOLDENSAFEBETS May. 7 at 3:22 AM

$ABEO 🐂🧃

0 · Reply

FitzCatalyst May. 6 at 7:57 PM

$ABEO hit that hod close

0 · Reply

alexpitti May. 6 at 7:31 PM

curious what the market wants from $ABEO. they kinda already gave Q2 guidance. i guess just reiterating that is good enough

2 · Reply

trichomy May. 6 at 4:40 PM

$INMB $INMB $ABEO $KRYS $MESO $IBRX We are in the eye of the storm . Volume already way up. This is the calm before tomorrow Booyah! Wake up people! 🔥 🔥 INMB 🔥 🔥

2 · Reply

Captenotwo May. 6 at 4:08 PM

$ABEO where’s creditgoo? Love when he’s wrong. I make money. Cheers, Cap

1 · Reply

FitzCatalyst May. 6 at 2:45 PM

$ABEO lets gooo

0 · Reply

trichomy May. 5 at 9:38 PM

$INMB $INMB expands collab with Anthony Nolan charity for umbilical cord tissue supply to advance CORDStrom hucMSC platform — targeting RDEB (CORDStrom-col7a), solid tumors (TRAIL), OA & more. Prepping for commercial approval! Strong supply deal + regulatory momentum in hot cell/gene therapy & rare disease space. $ABEO $KRYS $MESO $IBRX #biotech #celltherapy #RDEB https://www.stocktitan.net/news/INMB/i-nmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cord-r715r3sueyi2.html

1 · Reply

Po556677 May. 5 at 7:23 PM

$ABEO What ever the patient count is .......one thing is a is very clear/ABEO is an extremely undervalued company that will be profitable soon

0 · Reply

alcacer123 May. 5 at 7:00 PM

$ABEO In February they performed multiple biopsies. Multiple biopsies are supposed to be more than two, so they'll be three or four. How many did they do in March and April? Hopefully five or six. Currently, there are 226 executives and employees. They just hired a genetic testing expert. They're all focused on seeing patients and reaching ten per month, and adding two or three more centers.

0 · Reply

Market Cap	335.61M
Revenue (ttm)	5.82M
Net Income (ttm)	71.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,223.02%
Debt to Equity Ratio	0.13

Volume	853,800
Avg Vol	1,238,756
Day's Range	N/A - N/A
Shares Out	56.88M
Stochastic %K	80%
Beta	1.35
Analysts	Strong Sell
Price Target	$19.57